Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02276313




Registration number
NCT02276313
Ethics application status
Date submitted
22/10/2014
Date registered
28/10/2014
Date last updated
15/08/2022

Titles & IDs
Public title
BIOLUX P-III All-Comers Passeo-18 Lux Registry
Scientific title
BIOTRONIK - A Prospective, International, Mulit-centre, Post-market All-comers Registry to Assess the Clinical Performance of the Passeo-18 Lux Paclitaxel Releasing Balloon Catheter in Infrainguinal Arteries - III
Secondary ID [1] 0 0
C1211
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Atherosclerosis 0 0
Peripheral Artery Disease 0 0
Condition category
Condition code
Cardiovascular 0 0 0 0
Diseases of the vasculature and circulation including the lymphatic system

Intervention/exposure
Study type
Observational
Patient registry
Target follow-up duration
Target follow-up type
Description of intervention(s) / exposure
Treatment: Devices - Passeo-18 Lux

Treatment: Devices: Passeo-18 Lux
Endovascular Therapy
Intervention code [1] 0 0
Treatment: Devices
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Freedom from Major Adverse Events (MAE)
Timepoint [1] 0 0
6 months
Primary outcome [2] 0 0
Freedom from clinically-driven Target Lesion Revascularization (TLR)
Timepoint [2] 0 0
12 months
Secondary outcome [1] 0 0
Freedom from clinically-driven TLR
Timepoint [1] 0 0
6 and 24 months
Secondary outcome [2] 0 0
Freedom from clinically-driven Target Vessel Revascularization (TVR)
Timepoint [2] 0 0
6 and 24 months
Secondary outcome [3] 0 0
Primary patency
Timepoint [3] 0 0
12 and 24 months
Secondary outcome [4] 0 0
Freedom from MAE
Timepoint [4] 0 0
12 and 24 months
Secondary outcome [5] 0 0
Change in mean Ankle Brachial Index
Timepoint [5] 0 0
6, 12 and 24 months
Secondary outcome [6] 0 0
Amputation-free survival
Timepoint [6] 0 0
6, 12 and 24 months
Secondary outcome [7] 0 0
Patient-reported outcomes assessment: Pain score, Walking Impairment Questionnaire
Timepoint [7] 0 0
6, 12 and 24 months
Secondary outcome [8] 0 0
Clinical Success: Improvement in Rutherford classification compared to the pre-procedure Rutherford classification
Timepoint [8] 0 0
6, 12 and 24 months
Secondary outcome [9] 0 0
Device success
Timepoint [9] 0 0
Day 0
Secondary outcome [10] 0 0
Technical success
Timepoint [10] 0 0
Day 0
Secondary outcome [11] 0 0
Procedural success
Timepoint [11] 0 0
Participants will be followed for the duration of hospital stay, an expected average of 1-2 days

Eligibility
Key inclusion criteria
* Age = 18 years or minimum age as required by local regulations
* Subject must be willing to sign a Patient Data Release Form or Patient Informed Consent where applicable
* Lesion(s) in the infrainguinal arteries suitable for endovascular treatment treated with or scheduled to be treated with the Passeo-18 Lux drug releasing balloon
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Life expectancy = 1 year
* Subject is currently participating in another investigational drug or device study that has not reached ist primary endpoint yet
* Subject is pregnant or planning to become pregnant during the course of the study
* Failure to successfully cross the target lesion with a guide wire (successful crossing means tip of the guide wire distal to the target lesion in the absence of flow limiting dissections or perforations

Study design
Purpose
Duration
Selection
Timing
Prospective
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/10/2014
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/01/2022
Sample size
Target
Accrual to date
Final
880
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Cairns Hospital - Cairns
Recruitment hospital [2] 0 0
Lake Macquarie Private Hospital - Gateshead
Recruitment hospital [3] 0 0
Geelong University Hospital - Geelong
Recruitment hospital [4] 0 0
Hollywood Hospital - Nedlands
Recruitment hospital [5] 0 0
The Townsville Hospital - Townsville
Recruitment postcode(s) [1] 0 0
- Cairns
Recruitment postcode(s) [2] 0 0
- Gateshead
Recruitment postcode(s) [3] 0 0
- Geelong
Recruitment postcode(s) [4] 0 0
- Nedlands
Recruitment postcode(s) [5] 0 0
- Townsville
Recruitment outside Australia
Country [1] 0 0
Austria
State/province [1] 0 0
Graz
Country [2] 0 0
Austria
State/province [2] 0 0
Innsbruck
Country [3] 0 0
Belgium
State/province [3] 0 0
Brussels
Country [4] 0 0
Belgium
State/province [4] 0 0
Leuven
Country [5] 0 0
Belgium
State/province [5] 0 0
Liege
Country [6] 0 0
Belgium
State/province [6] 0 0
Tienen
Country [7] 0 0
Denmark
State/province [7] 0 0
Kolding
Country [8] 0 0
Finland
State/province [8] 0 0
Tampere
Country [9] 0 0
France
State/province [9] 0 0
Clermont-Ferrand
Country [10] 0 0
France
State/province [10] 0 0
Essey Les Nancy
Country [11] 0 0
France
State/province [11] 0 0
Grenoble
Country [12] 0 0
France
State/province [12] 0 0
Lyon
Country [13] 0 0
Germany
State/province [13] 0 0
Arnsberg
Country [14] 0 0
Germany
State/province [14] 0 0
Bad Krozingen
Country [15] 0 0
Germany
State/province [15] 0 0
Berlin
Country [16] 0 0
Germany
State/province [16] 0 0
Giessen
Country [17] 0 0
Germany
State/province [17] 0 0
Göttingen
Country [18] 0 0
Germany
State/province [18] 0 0
Jena
Country [19] 0 0
Germany
State/province [19] 0 0
Kiel
Country [20] 0 0
Germany
State/province [20] 0 0
München Pasing
Country [21] 0 0
Germany
State/province [21] 0 0
Rosenheim
Country [22] 0 0
Italy
State/province [22] 0 0
Firenze
Country [23] 0 0
Italy
State/province [23] 0 0
San Donato Milanese
Country [24] 0 0
Latvia
State/province [24] 0 0
Riga
Country [25] 0 0
Malaysia
State/province [25] 0 0
Kuala Lumpur
Country [26] 0 0
Netherlands
State/province [26] 0 0
Eindhoven
Country [27] 0 0
Netherlands
State/province [27] 0 0
Tilburg
Country [28] 0 0
Portugal
State/province [28] 0 0
Almada
Country [29] 0 0
Singapore
State/province [29] 0 0
Singapore
Country [30] 0 0
Slovakia
State/province [30] 0 0
Kosice
Country [31] 0 0
Spain
State/province [31] 0 0
Badalona
Country [32] 0 0
Spain
State/province [32] 0 0
Barcelona
Country [33] 0 0
Spain
State/province [33] 0 0
Madrid
Country [34] 0 0
Switzerland
State/province [34] 0 0
Lausanne
Country [35] 0 0
Switzerland
State/province [35] 0 0
Lugano
Country [36] 0 0
Switzerland
State/province [36] 0 0
Winterthur

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Biotronik AG
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
BIOLUX P-III is a prospective, international, multi-centre, postmarket all-comers registry to collect clinical performance data on the Passeo-18 Lux paclitaxel releasing balloon catheter in the treatment of atherosclerotic disease of the infrainguinal arteries.
Trial website
https://clinicaltrials.gov/study/NCT02276313
Trial related presentations / publications
Barry IP, Macarulay R, Brodmann M, Zeller T, Moscovic M, Dahm J, Troisi N, Tepe G, Wong J, Mwipatayi BP; BIOLUX P-III Global Registry Investigators. Sex-Related Outcomes Following Drug Balloon Angioplasty in Patients from the BIOLUX P-III Registry: A Subgroup Analysis. Cardiovasc Intervent Radiol. 2022 Jul;45(7):918-928. doi: 10.1007/s00270-022-03135-w. Epub 2022 Apr 20.
Mwipatayi BP, Barry IP, Brodmann M, Zeller T, Varcoe RL, Moscovic M, Chian JWC, Christensen JK, Yahaya SA, Oshin OA, Tepe G; BIOLUX P-III Global Registry Investigators. Twenty-Four-Month Outcomes of Drug-Coated Balloon in Diabetic Patients in the BIOLUX P-III Registry: A Subgroup Analysis. Ann Vasc Surg. 2021 Aug;75:237-252. doi: 10.1016/j.avsg.2021.02.050. Epub 2021 Apr 5.
Tepe G, Zeller T, Moscovic M, Corpataux JM, Christensen JK, Keirse K, Nano G, Schroeder H, Binkert CA, Brodmann M. Paclitaxel-Coated Balloon Angioplasty for the Treatment of Infrainguinal Arteries: 24-Month Outcomes in the Full Cohort of BIOLUX P-III Global Registry. Cardiovasc Intervent Radiol. 2021 Feb;44(2):207-217. doi: 10.1007/s00270-020-02663-7. Epub 2020 Oct 20. Erratum In: Cardiovasc Intervent Radiol. 2021 Jul;44(7):1155-1156. doi: 10.1007/s00270-021-02862-w.
Tepe G, Wang J, Corpataux JM, Pua U, Binkert CA, Moscovic M, Ghotbi R, Keirse K, Robertson D, Brodmann M. BIOLUX P-III Passeo-18 Lux All-Comers Registry: 24-Month Results in Below-the-Knee Arteries. Cardiovasc Intervent Radiol. 2021 Jan;44(1):10-18. doi: 10.1007/s00270-020-02586-3. Epub 2020 Sep 22. Erratum In: Cardiovasc Intervent Radiol. 2021 Aug;44(8):1307. doi: 10.1007/s00270-021-02861-x.
Tepe G, Zeller T, Moscovic M, Corpataux JM, Christensen JK, Keirse K, Nano G, Schroeder H, Binkert CA, Brodmann M. Paclitaxel-Coated Balloon for the Treatment of Infrainguinal Disease: 12-Month Outcomes in the All-Comers Cohort of BIOLUX P-III Global Registry. J Endovasc Ther. 2020 Apr;27(2):304-315. doi: 10.1177/1526602819898804. Epub 2020 Jan 28. Erratum In: J Endovasc Ther. 2021 Jun;28(3):489. doi: 10.1177/15266028211014307.
Public notes

Contacts
Principal investigator
Name 0 0
Gunnar Tepe, MD
Address 0 0
RoMed Klinikum Rosenheim
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT02276313